Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

GRAL vs ADPT: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ADPT Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 4–6 Matrix Metrics)

ADPT Overall Winner 6-Pillar Tally: GRAL 2 – 4 ADPT Matrix Metrics: GRAL 6 – 4 ADPT

As of Nov 16, 2026, Adaptive Biotechnologies Corporation (ADPT) is the stronger overall head-to-head candidate over GRAIL, Inc. (GRAL) in the Tradestie Institutional Equity Comparison Engine, winning 4–6 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). GRAL carries a Unified Composite Score of 54.5/100 (HOLD) at $105.60 (1.1x Forward P/E, -332.0% operating margin), whereas ADPT carries 43.8/100 (HOLD) at $27.87 (N/M Forward P/E, -16.2% operating margin).

  • Composite vs. Pillar Nuance: While GRAL currently prints a higher short-term Unified Composite Score (54.5/100 HOLD vs. ADPT 43.8/100 HOLD), ADPT captures the overall institutional head-to-head verdict (4–6 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (-16.2% vs. -332.0% operating margin) and revenue trajectory (-10.7% vs. +3.7% YoY).
  • Technical & Structure Timing Caution: GRAL is currently in a Breakdown options structure phase (RSI 37.7); meanwhile ADPT trades in a Markup technical trend (CONSOLIDATION options phase, RSI 51.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About GRAL vs ADPT
GRAL NASDAQ
GRAIL, Inc. Common Stock
Services-Medical Laboratories
$105.60
-8.88% 1D
Market Cap $5.2B
TTM Revenue $167M
Forward P/E 1.1x
Beta / 30D Vol 3.09β · 99% Vol
Unified Composite Score
54.5 / 100 HOLD
Tech 35.0 Fund 49.0 Flow 57.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 38
RSI-14: 37.7 · SMA20: $132.32 · SMA50: $121.37
ADPT NASDAQ Head-to-Head Winner
Adaptive Biotechnologies Corporation Common Stock
Biological Products, (No Disgnostic Substances)
$27.87
-4.03% 1D
Market Cap $4.7B
TTM Revenue $298M
Forward P/E N/M
Beta / 30D Vol 1.74β · 60% Vol
Unified Composite Score
43.8 / 100 HOLD
Tech 15.0 Fund 43.0 Flow 69.0 Mom 54.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (3.2% over 20 days), RSI 52
RSI-14: 51.8 · SMA20: $27.26 · SMA50: $26.98

6-Pillar Scorecard Institutional Category Breakdown (GRAL 2 – 4 ADPT)

Columns: Metric · GRAL · ADPT
1. Valuation Multiples GRAL
Forward P/E 1.1x N/M
Trailing P/E 1.1x N/M
PEG Ratio N/M N/M
EV / Revenue 31.6x 16.9x
2. Growth & Scale GRAL
Revenue Growth (YoY) +3.7% -10.7%
Earnings Growth (YoY) +0.0% -70.1%
TTM Revenue (USD) $167M $298M
Market Cap $5.2B $4.7B
3. Profitability & Quality ADPT
Gross Margin 46.7% 46.2%
Operating Margin -332.0% -16.2%
Net Profit Margin -243.8% -23.7%
Return on Equity (ROE) -17.3% -36.4%
4. Balance Sheet & Cash Flow ADPT
Cash Generation (TTM) -$312M -$8.8M
Cash Flow Margin N/A -3.0%
Net Cash / Leverage $57M Net Debt (0.03x D/E) $333M Net Debt (2.32x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ADPT
Options Structure Phase BREAKDOWN CONSOLIDATION
Current IV / %ile 93.0% (53rd %ile) 78.0% (36th %ile)
Put/Call OI Skew 0.81x (Call-Skewed) N/A
OBV Trend / Tech Phase DISTRIBUTION · Neutral ACCUMULATION · Markup
6. R&D & Supply-Chain Moat ADPT
OpEx & R&D Intensity N/A 62.4% of Rev ($186M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Diagnostics & Research Operator Diagnostics & Research Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: GRAL (6) vs ADPT (4)
Institutional Metric GRAL ADPT Criterion Row Edge
Market Capitalization
Scale
$5.2B $4.7B Larger Scale GRAL
Trailing P/E Ratio
Valuation
1.1x N/M Lower Multiple GRAL
Forward P/E Ratio
Valuation
1.1x N/M Lower Multiple GRAL
Revenue Growth (YoY)
Growth
+3.7% -10.7% Higher Growth GRAL
Operating Margin (TTM)
Profitability
-332.0% -16.2% Higher Margin ADPT
Net Profit Margin
Profitability
-243.8% -23.7% Higher Margin ADPT
Return on Equity (ROE)
Capital Efficiency
-17.3% -36.4% Higher ROE GRAL
52-Week Range Position
Momentum
51% ($42–$166) 78% ($12–$32) Stronger Trend ADPT
Beta / 30D Volatility
Risk Regime
3.09β · 99% Vol 1.74β · 60% Vol Lower Realized Risk ADPT
Unified Institutional Score
Composite Signal
54.5 / 100 (HOLD) 43.8 / 100 (HOLD) Higher Composite GRAL
Trailing 12M Revenue (USD)
Operating Scale
$167M $298M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
46.7% 46.2% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 31.6x EV/Rev N/M PEG · 16.9x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$312M ($57M Net Debt (0.03x D/E)) -$8.8M ($333M Net Debt (2.32x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ADPT +26.39 pp
GRAL: -10.36% · ADPT: +16.03%
3M Horizon GRAL +38.44 pp
GRAL: +50.96% · ADPT: +12.52%
6M Horizon ADPT +40.2 pp
GRAL: +77.03% · ADPT: +117.23%
1Y Horizon ADPT +70.18 pp
GRAL: +26.92% · ADPT: +97.1%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period GRAL Revenue ADPT Revenue GRAL Op. Margin ADPT Op. Margin Margin Leader
FY2018 N/A $60M N/A -89.4% ADPT
FY2019 N/A $90M N/A -92.1% ADPT
FY2020 N/A $100M N/A -155.3% ADPT
FY2021 N/A $150M N/A -135.4% ADPT
FY2022 N/A $190M N/A -108.0% ADPT
FY2023 $90M $170M -1627.6% -133.3% ADPT
FY2024 $130M $180M -1743.0% -90.8% ADPT
FY2025 $150M $280M -382.0% -20.6% ADPT

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
GRAL BREAKDOWN
12d in phase · OBV DISTRIBUTION
Current IV 93.0%
IV Percentile 53rd %ile
Put/Call OI Skew 0.81x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact GRAL Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ADPT CONSOLIDATION
69d in phase · OBV ACCUMULATION
Current IV 78.0%
IV Percentile 36th %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact ADPT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
GRAL Moat Profile Cyclical / Execution-Driven Positioning
Diagnostics & Research Operator
Competes within the Diagnostics & Research value chain with $5.2B market capitalization and -332.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ADPT Moat Profile Cyclical / Execution-Driven Positioning
Diagnostics & Research Operator
Competes within the Diagnostics & Research value chain with $4.7B market capitalization and -16.2% operating margin.
OpEx & R&D Reinvestment 62.4% of Rev ($186M)
90D Engineering Disclosures 0 Published

Investor FAQ GRAL vs ADPT Key Questions & Quantitative Answers

As of Nov 16, 2026, Adaptive Biotechnologies Corporation (ADPT) is the stronger overall head-to-head candidate over GRAIL, Inc. (GRAL) in the Tradestie Institutional Equity Comparison Engine, winning 4–6 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). GRAL carries a Unified Composite Score of 54.5/100 (HOLD) at $105.60 (1.1x Forward P/E, -332.0% operating margin), whereas ADPT carries 43.8/100 (HOLD) at $27.87 (N/M Forward P/E, -16.2% operating margin). Composite vs. Pillar Nuance: While GRAL currently prints a higher short-term Unified Composite Score (54.5/100 HOLD vs. ADPT 43.8/100 HOLD), ADPT captures the overall institutional head-to-head verdict (4–6 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (-16.2% vs. -332.0% operating margin) and revenue trajectory (-10.7% vs. +3.7% YoY). Technical & Structure Timing Caution: GRAL is currently in a Breakdown options structure phase (RSI 37.7); meanwhile ADPT trades in a Markup technical trend (CONSOLIDATION options phase, RSI 51.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

GRAL leads the Growth & Scale pillar: GRAL posts +3.7% YoY revenue growth and +0.0% YoY earnings growth on $167M TTM revenue (46.7% gross margin, -332.0% operating margin), compared with ADPT at -10.7% YoY revenue growth and -70.1% YoY earnings growth on $298M TTM revenue (46.2% gross margin, -16.2% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), GRAL cumulative revenue shifted +66.7% while ADPT shifted +366.7%. In operating R&D and SG&A reinvestment, GRAL deploys N/A (0 90-day corporate R&D disclosures) versus 62.4% of Rev ($186M) (0 disclosures) for ADPT.

GRAL screens cheaper on headline valuation multiples. GRAL trades at 1.1x Forward P/E, 1.1x Trailing P/E, N/M PEG, and 31.6x EV/Revenue (unreported FCF margin), whereas ADPT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 16.9x EV/Revenue (-3.0% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against GRAL (-17.3% ROE) versus ADPT (-36.4% ROE) capital efficiency.

In options market volatility and institutional positioning, GRAL carries 93.0% implied volatility (53rd %ile, Balanced (25th–60th %ile)), a 0.81x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (3.09β · 99% Vol realized risk). By comparison, ADPT carries 78.0% implied volatility (36th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.74β · 60% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.